News and Trends 26 Oct 2018
Danish Biotech Closes €79M Series C to Develop Inhaled Lung Disease Drug
The Danish company Galecto Biotech can breathe a contented sigh. Its Series C funding round has raised €79M to finance a Phase II/III trial of its inhaled drug for a deadly lung disease. The amount raised is 30% higher than the company’s initial €60M goal, Galecto’s CEO, Hans Schambye, told me. “Being able to raise […]